Menu Home » Investor Relations Investor Relations Your trusted and focused solution partner since 1923 Share Ticker Elos Medtech B (ELOS B) Latest +/- % Ask Bid 340 5 1.49 335 327 Last update: 24 November 2021, 2:30 This post is also available in: Svenska Elos Medtech AB (publ) is a Swedish limited liability company whose B share is traded on the Small Cap list of the NASDAQ Stockholm AB. Elos Medtech’s corporate governance is based on Swedish legislation and the listing agreement with the NASDAQ Stockholm AB. Interim reports and annual reports are available on the website in the form of printable pdf files. Interim and year-end reports are not sent by post to the shareholders. As previously, the annual report is forwarded by post to the shareholders who so request. For IR questions and information, please send an e-mail to: IR contact SHORT NAME: ELOS B ISIN: SE0000120776 LEI CODE: 529900I5MSNU451FL670 Get the latest first Subscribe now to receive Elos Medtech's press releases and financial reports directly to your inbox. SUBSCRIBE CALENDAR Feb 24, 2022 Year-end Report 2021 April, 2022 Annual Report 2021 April 26, 2022 Interim Report Q1, 2022 May 3, 2022 Annual General Meeting 2022 Aug 18, 2022 Interim Report Q2, 2022 Oct 21, 2022 Interim Report Q3, 2022 Feb 23, 2023 Year-end Report 2022 PRESS RELEASES & REGULATORY INFORMATION Elos Medtech Interim Report January 1 - September 30, 2021 20 Oct 2021, 08:00 Elos Medtech Nomination Committee appointed for the 2022 Annual General Meeting 27 Sep 2021, 11:30 Resolutions from Extraordinary General Meeting of Elos Medtech AB (publ) 2021 13 Aug 2021, 15:45 PRESS RELEASES & REGULATORY INFORMATION Elos Medtech Interim Report January 1 - September 30, 2021 20 Oct 2021, 08:00 Financial / IR information STAY UPDATED! Subscribe to our newsletter SUBSCRIBE Copyright © 2021 by Elos Medtech AB. All rights reserved. Cookies & Privacy Policy Follow us: This website uses cookies to provide you with the best browsing experience. Find out more or adjust your settings. Accept